Agent | Mechanism of action | Location | Regimen |
---|---|---|---|
Etanercept | TNFi | USA and Europe | Monotherapy |
Adalimumab | TNFi | USA and Europe | Monotherapy |
Infliximab | TNFi | USA and Europe | In combination with MTX only |
Certolizumab pegol | TNFi | USA and Europe | Monotherapy |
Golimumab | TNFi | USA and Europe | In combination with MTX only |
Tocilizumab | IL-6 receptor inhibitor | USA and Europe | Monotherapy |
Anakinra | IL-1 receptor inhibitor | USA | Monotherapy |
Abatacept | Inhibitor of T-cell activation (costimulation modulator) | USA | Monotherapy |
Rituximab | Anti-CD20 | USA and Europe | In combination with a DMARD only |
Tofacitinib | JAK inhibitor | USA | Monotherapy |
DMARD, disease-modifying antirheumatic drug; IL, interleukin; JAK, janus kinase; MTX, methotrexate; TNFi, tumour necrosis factor inhibitor.